KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Operating Expenses: 2010-2025

Historic Operating Expenses for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $154.6 million.

  • Emergent BioSolutions' Operating Expenses fell 32.58% to $154.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $670.4 million, marking a year-over-year decrease of 47.15%. This contributed to the annual value of $1.2 billion for FY2024, which is 35.11% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Operating Expenses of $154.6 million as of Q3 2025, which was up 10.98% from $139.3 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Operating Expenses ranged from a high of $630.8 million in Q2 2023 and a low of $139.3 million during Q2 2025.
  • Its 3-year average for Operating Expenses is $308.6 million, with a median of $260.6 million in 2024.
  • As far as peak fluctuations go, Emergent BioSolutions' Operating Expenses skyrocketed by 100.44% in 2023, and later plummeted by 69.60% in 2025.
  • Emergent BioSolutions' Operating Expenses (Quarterly) stood at $437.9 million in 2021, then fell by 11.97% to $385.5 million in 2022, then fell by 16.89% to $320.4 million in 2023, then plummeted by 36.27% to $204.2 million in 2024, then slumped by 32.58% to $154.6 million in 2025.
  • Its Operating Expenses stands at $154.6 million for Q3 2025, versus $139.3 million for Q2 2025 and $172.3 million for Q1 2025.